Guidance Archives - Page 26 of 637

1 minute read

Evolv Technologies Lowers FY24 Sales Guidance from $115.00M to $100.00M Vs. $114.6M Estimate

May 10, 7:33 AM

Company Comments on Outlook for 2024 The Company today commented on its business outlook for 2024. The Company's outlook is based on the current indications for its business, which may change at any

EVLV

1 minute read

FTC Solar Expects Q2 Revenue $10.5M–$15.5M Vs $23.58M Est

By Benzinga Newsdesk

May 10, 6:37 AM

Outlook We expect second quarter 2024 revenue at the mid-point to be slightly up from the first quarter. We continue to expect revenue to be weighted toward the second half of the year, and that the

FTCI

1 minute read

Novavax Updates 2024 Guidance: Expects Combined Revenue And Sanofi Agreement Payments Of $970M-$1.17B (Prior $800M-$1B); And Combined R&D And SG&A Of $700M-$750M (Prior $700M-$800M)

By Benzinga Newsdesk

May 10, 3:23 AM

Financial Framework Novavax is updating its Full Year 2024 Financial Guidance and expects to achieve the following objectives: Full Year 2024 Guidance $ in millions Prior (as

NVAX

1 minute read

CRH 2024 Outlook: Expects EPS Of $5.15-$5.45 Vs $5.4 Est, And Adjusted EBITDA Of $6.55B-$6.85B

By Benzinga Newsdesk

May 10, 2:42 AM

2024 Guidance (in $ billions, except per share data) Low High Net income

CRH

1 minute read

AMN Healthcare Services Sees Q2 Revenue $730M-$750M Vs $776.83M Est.

By Benzinga Newsdesk

May 9, 7:40 PM

Second Quarter 2024 OutlookMetricGuidance*Consolidated revenue$730 - $750 millionGross margin30.7% - 31.2%SG&A as percentage of revenue21.5% - 22.0%Operating margin3.0% - 3.7%Adjusted EBITDA margin11.0% -

AMN

1 minute read

Alarm.com Sees Q2 Saas And License Revenue $153.8M-$154M; FY24 SaaS And License Revenue $624.5M-$625M; FY24 EPS $2.14-$2.16 Vs $2.14 Est.; Total Revenue $914.5M-$931M Vs $925.18M Est.

By Benzinga Newsdesk

May 9, 6:45 PM

For the second quarter of 2024:SaaS and license revenue is expected to be in the range of $153.8 million to $154.0 million.For the full year 2024:SaaS and license revenue is expected to be in the range of $624.5 million

ALRM

1 minute read

Evolent Health Sees Q2 Revenue $625M-$645M Vs $606.64M Est.; FY24 Revenue $2.53B-$2.60B Vs $2.47B Est.

By Benzinga Newsdesk

May 9, 4:24 PM

Second Quarter 2024 GuidanceFor the three months ended June 30, 2024, revenue is expected to be in the range of approximately $625.0 million to $645.0 million. Adjusted EBITDA is expected to be in the range of

EVH

1 minute read

Diodes Sees Q2 Revenue ~$316M +/- 3% Vs $327.62M Est

By Benzinga Newsdesk

May 9, 4:20 PM

Business OutlookGary Yu further commented, "For the second quarter of 2024, we expect revenue to be approximately $316 million, plus or minus 3 percent, representing a 4.6% sequential increase at the mid-point and

DIOD

1 minute read

Genpact Raises FY24 EPS Range From $3.00-$3.03 To $3.01-$3.04 Vs $3.01 Est.; Revenue $4.59B-$4.63B Vs $4.59B Est.

By Benzinga Newsdesk

May 9, 4:15 PM

OutlookGenpact's updated outlook for the full year 2024 is as follows:Total revenue in the range of $4.59 billion to $4.63 billion, representing year-over-year growth of approximately 2.5% to 3.5% as reported, or 2.7% to

1 minute read

Insulet Expects Q2 Revenue Growth Of 15%-18%; Raising Its Expected Revenue Growth From 12%-17% To 14%-18%

By Benzinga Newsdesk

May 9, 4:13 PM

2024 Outlook:Revenue Guidance (in constant currency):For the year ending December 31, 2024, the Company is raising its expected revenue growth to a range of 14% to 18% (previously 12% to 17%). Revenue growth ranges by

PODD